▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / ZVSA

ZVSA — ZyVersa Therapeutics, Inc.

—
OTC · Health Care · Pharmaceuticals · CIK 1859007 ·
Last close
$0.10
Market Cap
$805.5K
52W High
$0.20
52W Low
$0.08
ADV30
6,270
Next earnings
2026-08-24
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 — -1,304,698 -1,793,381 742,223 302,660 14,866,518
Dec 2025 0 — -551,858 -678,572 347,901 101,778 12,734,687
Sep 2025 0 — -2,104,227 -19,805,559 1,040,260 527,978 12,765,827
Jun 2025 0 — -2,044,132 -2,211,317 19,641,111 72,086 13,541,337

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-4,141,447
Investing CF
—
Financing CF
$2,832,575
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-3.97
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-139,378,318
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-24,814,327
Pretax Income TTM
$-25,340,488
Interest Exp TTM
$526,161
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -6,844,787 -24,952,378 347,901 12,734,687 — -5,114,381
Dec 2024 0 -9,136,834 -9,413,435 20,599,414 12,082,967 — -7,519,534
Dec 2023 0 -14,420,774 -98,297,946 22,114,284 11,039,686 — -8,720,819
Dec 2022 0 -13,013,064 -14,047,607 118,506,271 18,511,943 — -1,494,641

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.80

Peers — same industry

TickerNameMarket CapLastDaily %
ATXI AVENUE THERAPEUTICS, INC. $848.8K $0.26 —
EVFM Evofem Biosciences, Inc. $927.7K $0.01 —
VBIO Valion Bio, Inc. $689.1K $0.17 —
SKVI SKINVISIBLE, INC. $972.7K $0.18 —
BDRX Biodexa Pharmaceuticals Plc $1.08M $1.20 —

News headlines (Yahoo Finance, 1h cache)

ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
2026-03-31 21:05 · Yahoo
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-13 20:55 · Yahoo
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
2025-11-19 21:20 · Yahoo
Delisting of Securities from The Nasdaq Stock Market
2025-09-24 11:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →